phenylacetyl iodide | 80317-74-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: phenylacetyl iodide
• 英文别名: phenylacetyliodide；Phenylacetyliodid；2-phenylacetyl iodide
• CAS: 80317-74-4
• 化学式: C₈H₇IO
• 分子量: 246.047
• InChiKey: HJWGSCXFRXXIGV-UHFFFAOYSA-N

物化性质

• 沸点：
  84-88 °C(Press: 4 Torr)
• 密度：
  1.780±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  phenylacetyl iodide 、 氰化亚铜 以 乙腈 为溶剂， 反应 1.0h， 以50%的产率得到2-氧代-3-苯基丙腈
  参考文献：
  名称：

  Hoffmann, H. M. R.; Haase, Klaus; Ismail, Zeinhom M., Chemische Berichte, 1982, vol. 115, # 12, p. 3880 - 3885

  摘要：

  DOI：
• 作为产物：
  描述：

  trans-[(phenylacetyl)bis(triphenylphosphine)palladium(II)(Cl)] 在 碘 作用下， 以 二氯甲烷 为溶剂， 生成 phenylacetyl iodide
  参考文献：
  名称：

  通过卤素与乙酰基，（苯基乙酰基）-和苯甲酰氯双（三苯基膦）铂（II）与乙酰基，（苯乙酰基）-和苯甲酰氯（三苯基膦）钯（II）络合物的反应形成羧酸卤化物

  摘要：

  DOI：

  10.1021/om00109a007

文献信息

• [EN] FLUORINATED LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS FLUORÉS DE LA LYSYL OXYDASE-LIKE 2 ET UTILISATIONS DESDITS INHIBITEURS
  申请人：PHARMAKEA INC

  公开号：WO2016144703A1

  公开（公告）日：2016-09-15

  Described herein are compounds that are LOXL2 inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with LOXL2 activity.

  本文描述的是一种LOXL2抑制剂化合物，制备这种化合物的方法，包含这种化合物的药物组合物和药物，以及使用这种化合物治疗与LOXL2活性相关的疾病、病症或疾病的方法。
• COELENTERAMIDE ANALOGS
  申请人：Hosoya Takamitsu

  公开号：US20110288280A1

  公开（公告）日：2011-11-24

  There has been a need for coelenteramide analogs or the like that produce fluorescent proteins which exhibit different fluorescent characteristics from those of the existing fluorescent proteins. Disclosed is a compound represented by general formula (1) (wherein R 1 represents a substituted or unsubstituted aryl, a substituted or unsubstituted arylalkyl, a straight or branched alkyl which may optionally be substituted with an alicyclic group, an alicyclic group or a heterocyclic group; R 2 represents hydrogen or —(SO 2 )R 4 ; R 3 represents hydrogen, hydroxyl, methoxy or acetoxy; R 4 represents a substituted or unsubstituted aryl, a substituted or unsubstituted arylalkyl or a straight or branched alkyl which may optionally be substituted with an alicyclic group; and X 1 represents —C(═S)— or —SO 2 —).

  已经有了对产生发出与现有荧光蛋白不同荧光特性的珊瑚胺类似物等的需求。公开了一种由通式（1）表示的化合物（其中R1代表取代或未取代芳基，取代或未取代芳基烷基，可选择性地取代有脂环基的直链或支链烷基，脂环基或杂环基；R2代表氢或—(SO2)R4；R3代表氢，羟基，甲氧基或乙酰氧基；R4代表取代或未取代芳基，取代或未取代芳基烷基或可选择性地取代有脂环基的直链或支链烷基；X1代表—C(═S)—或—SO2—）。
• Novel antihistaminic piperidine derivatives and intermediates for the preparation thereof
  申请人：——

  公开号：US20030022919A1

  公开（公告）日：2003-01-30

  This invention relates to novel piperidine derivatives of formula (I) and a process for the preparation thereof. 1 wherein R 1 is H or C 1 -C 6 alkyl wherein the C 1 -C 6 alkyl moiety is straight or branched; R 2 is —COOH or —COOalkyl wherein the alkyl moiety has from 1 to 6 carbon atoms and is straight or branched; or stereoisomers or pharmaceutically acceptable acid addition salt thereof.

  这项发明涉及到公式（I）的新型哌啶衍生物以及其制备方法。其中R1为H或C1-C6烷基，其中C1-C6烷基基团是直链或支链；R2为—COOH或—COO烷基，其中烷基基团含有1至6个碳原子且为直链或支链；或其立体异构体或药学上可接受的酸盐。
• SUBSTITUTED AZETIDINONES
  申请人：Bannister Thomas

  公开号：US20100144698A1

  公开（公告）日：2010-06-10

  Compounds are provided which have the structure Wherein A, B, C, D, m, Y, Ra, Rc, Rd, and Rd′ are as described herein, and which are useful as inhibitors of tryptase, thrombin, trypsin, Factor Xa, Factor VIIa, Factor XIa, and urokinase-type plasminogen activator and may be employed in preventing and/or treating asthma, chronic asthma, allergic rhinitis, and thrombotic disorders.

  提供了具有以下结构的化合物： 其中A，B，C，D，m，Y，Ra，Rc，Rd和Rd'如本文所述，并且可用作抑制剂尝试酶，凝血酶，胰蛋白酶，因子Xa，因子VIIa，因子XIa和尿激酶型纤溶酶原激活剂，并可用于预防和/或治疗哮喘，慢性哮喘，过敏性鼻炎和血栓性疾病。
• C-Met Modulators and Method of Use
  申请人：Bannen Lynne Canne

  公开号：US20120022065A1

  公开（公告）日：2012-01-26

  The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. More specifically, the invention provides quinazolines and quinolines which inhibit, regulate, and/or modulate kinase receptor, particularly c-Met, KDF, c-Kit, flt-3 and flt-4, signal transduction pathways related to the changes in cellular activities as mentioned above, compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions. The present invention also provides methods for making compounds as mentioned above, and compositions which contain these compounds.

  本发明提供了一种用于调节蛋白激酶酶活性以调节细胞活动（如增殖、分化、程序性细胞死亡、迁移和化学侵袭）的化合物。更具体地，本发明提供了对c-Met、KDF、c-Kit、flt-3和flt-4等激酶受体进行抑制、调节和/或调节信号转导途径，以及与上述细胞活动变化相关的化合物、含有这些化合物的组合物和使用它们治疗激酶依赖性疾病和病况的方法。本发明还提供了制备上述化合物的方法和含有这些化合物的组合物。